What amount sold does Groff North America, LLC report in Form D filings?

The latest linked filings report $13.1M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Groff North America, LLC's most recent SEC filing?

Groff North America, LLC's most recent Form D filing was on 2023-07-14.

How many investors does Groff North America, LLC have?

The most recent Form D filing lists 24 investor(s).

What type of securities does Groff North America, LLC offer?

Groff North America, LLC's SEC Form D filings indicate equity offerings.

Groff North America, LLC

CIK: 0001985457·Pharmaceuticals·RED LION, PA·Limited Liability Company·Founded 2019

Reported Sold

$13,098,333

Total Filings

Identified Offerings

Last Filed

Jul 14, 2023

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Jul 14, 2023Form D — New notice

Reported sold: $13,098,333 · Target: $17,598,333

Rule 506(b)·24 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$13,098,333

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Robert A. Kinsley, II

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Jul 14, 2023	New	$17,598,333	$13,098,333	24

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Maxona Pharmaceuticals, Inc.

Pharmaceuticals

Offering target: $12,000,000

Filed Aug 14, 2026